Free Trial
NASDAQ:KZR

Kezar Life Sciences Q3 2024 Earnings Report

Kezar Life Sciences logo
$3.90 +0.03 (+0.64%)
As of 01:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kezar Life Sciences EPS Results

Actual EPS
-$2.78
Consensus EPS
-$3.03
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

Kezar Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kezar Life Sciences Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Earnings Documents

Kezar Life Sciences Earnings Headlines

William Blair Analysts Raise Earnings Estimates for KZR
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Kezar Life Sciences (KZR) to Release Earnings on Tuesday
See More Kezar Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kezar Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kezar Life Sciences and other key companies, straight to your email.

About Kezar Life Sciences

Kezar Life Sciences (NASDAQ:KZR), a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

View Kezar Life Sciences Profile

More Earnings Resources from MarketBeat